These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

734 related articles for article (PubMed ID: 25087214)

  • 21. Stevens-Johnson syndrome and toxic epidermal necrolysis: efficacy of intravenous immunoglobulin and a review of treatment options.
    Teo L; Tay YK; Liu TT; Kwok C
    Singapore Med J; 2009 Jan; 50(1):29-33. PubMed ID: 19224081
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A retrospective analysis of mortality risk and immunosuppressive therapy for Stevens-Johnson Syndrome and toxic epidermal necrolysis syndrome using the TriNetX research network.
    Ozhathil DK; Powell CM; Corley CV; Golovko G; Song J; El Ayadi A; Wolf SE; Kahn SA
    Burns; 2024 Feb; 50(1):75-86. PubMed ID: 37734977
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Intravenous immunoglobulin use in patients with toxic epidermal necrolysis and Stevens-Johnson syndrome.
    Mittmann N; Chan B; Knowles S; Cosentino L; Shear N
    Am J Clin Dermatol; 2006; 7(6):359-68. PubMed ID: 17173470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis.
    Houschyar KS; Tapking C; Borrelli MR; Puladi B; Ooms M; Wallner C; Duscher D; Pförringer D; Rein S; Reumuth G; Schulz T; Nietzschmann I; Maan ZN; Grieb G; Philipp-Dormston WG; Branski LK; Siemers F; Lehnhardt M; Schmitt L; Yazdi AS
    J Wound Care; 2021 Dec; 30(12):1012-1019. PubMed ID: 34881995
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of systemic immunomodulatory treatment and prognostic factors on chronic ocular complications in Stevens-Johnson syndrome.
    Kim DH; Yoon KC; Seo KY; Lee HS; Yoon SC; Sotozono C; Ueta M; Kim MK
    Ophthalmology; 2015 Feb; 122(2):254-64. PubMed ID: 25262319
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Stevens-Johnson syndrome and toxic epidermal necrolysis in Asian children.
    Koh MJ; Tay YK
    J Am Acad Dermatol; 2010 Jan; 62(1):54-60. PubMed ID: 19811851
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of additional i.v. immunoglobulin to steroid therapy in Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Aihara M; Kano Y; Fujita H; Kambara T; Matsukura S; Katayama I; Azukizawa H; Miyachi Y; Endo Y; Asada H; Miyagawa F; Morita E; Kaneko S; Abe R; Ochiai T; Sueki H; Watanabe H; Nagao K; Aoyama Y; Sayama K; Hashimoto K; Shiohara T;
    J Dermatol; 2015 Aug; 42(8):768-77. PubMed ID: 25982480
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Open trial of ciclosporin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis.
    Valeyrie-Allanore L; Wolkenstein P; Brochard L; Ortonne N; Maître B; Revuz J; Bagot M; Roujeau JC
    Br J Dermatol; 2010 Oct; 163(4):847-53. PubMed ID: 20500799
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intravenous immunoglobulin in the treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis: a meta-analysis with meta-regression of observational studies.
    Barron SJ; Del Vecchio MT; Aronoff SC
    Int J Dermatol; 2015 Jan; 54(1):108-15. PubMed ID: 24697283
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stevens-Johnson syndrome and toxic epidermal necrolysis: a 10-year experience in a burns unit.
    Houschyar KS; Tapking C; Borrelli MR; Nietzschmann I; Puladi B; Ooms M; Rein S; Houschyar M; Duscher D; Maan ZN; Reumuth G; Branski LK; Modabber A; Kluwig D; Schmitt L; Philipp-Dormston WG; Yazdi AS; Siemers F
    J Wound Care; 2021 Jun; 30(6):492-496. PubMed ID: 34121430
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Intravenous immunoglobulin treatment for Stevens-Johnson syndrome and toxic epidermal necrolysis: a prospective noncomparative study showing no benefit on mortality or progression.
    Bachot N; Revuz J; Roujeau JC
    Arch Dermatol; 2003 Jan; 139(1):33-6. PubMed ID: 12533161
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Retrospective analysis of Stevens-Johnson syndrome and toxic epidermal necrolysis in 87 Japanese patients--Treatment and outcome.
    Yamane Y; Matsukura S; Watanabe Y; Yamaguchi Y; Nakamura K; Kambara T; Ikezawa Z; Aihara M
    Allergol Int; 2016 Jan; 65(1):74-81. PubMed ID: 26666483
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluation of Combination Therapy With Etanercept and Systemic Corticosteroids for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: A Multicenter Observational Study.
    Zhang J; Lu CW; Chen CB; Wang CW; Chen WT; Cheng B; Ji C; Chung WH
    J Allergy Clin Immunol Pract; 2022 May; 10(5):1295-1304.e6. PubMed ID: 35131514
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Stevens-Johnson Syndrome and toxic epidermal necrolysis: a multi-aspect comparative 7-year study from the People's Republic of China.
    Sun J; Liu J; Gong QL; Ding GZ; Ma LW; Zhang LC; Lu Y
    Drug Des Devel Ther; 2014; 8():2539-47. PubMed ID: 25548516
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful Use of Cyclosporin A for Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis in Three Children.
    St John J; Ratushny V; Liu KJ; Bach DQ; Badri O; Gracey LE; Ho AW; Raff AB; Sugai DY; Schalock P; Kroshinsky D
    Pediatr Dermatol; 2017 Sep; 34(5):540-546. PubMed ID: 28884910
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stevens Johnson syndrome and toxic epidermal necrolysis - an Australian analysis of treatment outcomes and mortality.
    Tran AK; Sidhu S
    J Dermatolog Treat; 2019 Nov; 30(7):718-723. PubMed ID: 30632424
    [No Abstract]   [Full Text] [Related]  

  • 37. Intravenous immunoglobulins, cyclosporine, and best supportive care in epidermal necrolysis: Diverse effects on systemic inflammation.
    Schmidt V; Lalevée S; Traidl S; Ameri M; Ziadlou R; Ingen-Housz-Oro S; Barau C; de Prost N; Nägeli M; Mitamura Y; Meier-Schiesser B; Navarini AA; French LE; Contassot E; Brüggen MC
    Allergy; 2023 May; 78(5):1280-1291. PubMed ID: 36463488
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cyclosporine for SJS/TEN: a case series and review of the literature.
    Reese D; Henning JS; Rockers K; Ladd D; Gilson R
    Cutis; 2011 Jan; 87(1):24-9. PubMed ID: 21323097
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A 10-year retrospective cohort study of the management of toxic epidermal necrolysis and Stevens-Johnson syndrome in a New South Wales state referral hospital from 2006 to 2016.
    Chan L; Cook DK
    Int J Dermatol; 2019 Oct; 58(10):1141-1147. PubMed ID: 30908601
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical characteristics of childhood erythema multiforme, Stevens-Johnson syndrome and toxic epidermal necrolysis in Taiwanese children.
    Lam NS; Yang YH; Wang LC; Lin YT; Chiang BL
    J Microbiol Immunol Infect; 2004 Dec; 37(6):366-70. PubMed ID: 15599469
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 37.